A grab bag of shorts (Jan 2019) | Value Investing News

A grab bag of shorts (Jan 2019)

  • Some pharma companies decide to engage in an adversarial relationship with PBMs, the middlemen who sit in between payors and drug makers.
  • I believe that this stock is fairly overpriced because Wall Street doesn’t understand the business model and the nature of Horizon’s “innovation”.
  • CBMG ($350M mkt cap): This Chinese reverse merger has pivoted its business towards development-stage biotech.
No votes yet
Article Link: 
Shared Count: 
Value Score: